Literature DB >> 6117308

Cerebrospinal fluid concentrations of propranolol, pindolol and atenolol in man: evidence for central actions of beta-adrenoceptor antagonists.

E A Taylor, D Jefferson, J D Carroll, P Turner.   

Abstract

1 Single and multiple oral dose studies of the penetration into CSF of three beta-adrenoceptor antagonists were performed in groups of patients needing lumbar puncture as part of their neurological investigation. Propranolol, pindolol and atenolol were chosen because of their differing physico-chemical properties. 2 The CSF concentration of propranolol (lipid-soluble) and pindolol (moderately lipid-soluble) was proportional to the free plasma concentration and was similar to, although generally lower than, that theoretically predicted. 3 The CSF concentrations of the poorly lipid-soluble atenolol were similar in different patients and were independent of plasma concentration. This may be due to the slow rate of diffusion of atenolol into CSF preventing the predicted concentrations being achieved.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6117308      PMCID: PMC1401910          DOI: 10.1111/j.1365-2125.1981.tb01264.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  20 in total

1.  The metabolism and distribution of the selective adrenergic beta blocking agent, practolol.

Authors:  B Scales; M B Cosgrove
Journal:  J Pharmacol Exp Ther       Date:  1970-11       Impact factor: 4.030

2.  Absorption, distribution and excretion of alprenolol in man, dog and rat.

Authors:  N O Bodin; K O Borg; R Johansson; H Obianwu; R Svensson
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1974-10

3.  Disposition of propranolol. VI. Independent variation in steady-state circulating drug concentrations and half-life as a result of plasma drug binding in man.

Authors:  G H Evans; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1973 Jul-Aug       Impact factor: 6.875

4.  Further studies with propranolol in psychotic patients. Relation to initial psychiatric state, urinary catecholamines and 3-methoxy-4-hydroxyphenylglycol excretion.

Authors:  A Atsmon; I Blum; M Steiner; A Latz; H Wijsenbeek
Journal:  Psychopharmacologia       Date:  1972

5.  Plasma propranolol levels in adults with observations in four children.

Authors:  D G Shand; E M Nuckolls; J A Oates
Journal:  Clin Pharmacol Ther       Date:  1970 Jan-Feb       Impact factor: 6.875

6.  Hallucinations and propranolol.

Authors:  R D Hinshelwood
Journal:  Br Med J       Date:  1969-05-17

7.  Supracortical fluid: a monitor of albumin exchange in normal and injured brain.

Authors:  F A Matsen; C R West
Journal:  Am J Physiol       Date:  1972-03

8.  Studies on the absorption, distribution and excretion of propranolol in rat, dog and monkey.

Authors:  A Hayes; R G Cooper
Journal:  J Pharmacol Exp Ther       Date:  1971-02       Impact factor: 4.030

9.  A method for the fluorimetric determination of 4-(2-hydroxy-3-isopropylaminopropoxy)-indole (LB46), a beta-blocking agent, in plasma and urine.

Authors:  W L Pacha
Journal:  Experientia       Date:  1969-08-15

10.  High-dose propranolol in schizophrenia.

Authors:  G P Sheppard
Journal:  Br J Psychiatry       Date:  1979-05       Impact factor: 9.319

View more
  10 in total

Review 1.  Improving the prediction of the brain disposition for orally administered drugs using BDDCS.

Authors:  Fabio Broccatelli; Caroline A Larregieu; Gabriele Cruciani; Tudor I Oprea; Leslie Z Benet
Journal:  Adv Drug Deliv Rev       Date:  2011-12-21       Impact factor: 15.470

Review 2.  Psychiatric manifestations of Graves' hyperthyroidism: pathophysiology and treatment options.

Authors:  Robertas Bunevicius; Arthur J Prange
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 3.  Psychomotor performance and antihypertensive treatment.

Authors:  L Kalra; C G Swift; S H Jackson
Journal:  Br J Clin Pharmacol       Date:  1994-02       Impact factor: 4.335

4.  Exercise-induced increments in plasma levels of propranolol and noradrenaline.

Authors:  G A Hurwitz; J G Webb; T Walle; S A Bai; H B Daniell; L Gourley; C Boyd Loadholt; T E Gaffney
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

Review 5.  Clinical pharmacokinetics of cerebrospinal fluid.

Authors:  M Bonati; J Kanto; G Tognoni
Journal:  Clin Pharmacokinet       Date:  1982 Jul-Aug       Impact factor: 6.447

6.  Receptor occupancy in lumbar CSF as a measure of the antagonist activity of atenolol, metoprolol and propranolol in the CNS.

Authors:  T Kaila; R Marttila
Journal:  Br J Clin Pharmacol       Date:  1993-05       Impact factor: 4.335

7.  Nonlinear distribution of atenolol between plasma and cerebrospinal fluid.

Authors:  F M Gengo; S C Fagan; L N Hopkins; D Wagner; D P Schuster
Journal:  Pharm Res       Date:  1989-03       Impact factor: 4.200

Review 8.  The pharmacokinetics of lignocaine and beta-adrenoceptor antagonists in patients with acute myocardial infarction.

Authors:  S Nattel; G Gagne; M Pineau
Journal:  Clin Pharmacokinet       Date:  1987-11       Impact factor: 6.447

9.  Changes in neurotransmitter sensitivity in the mouse neocortical slice following propranolol and theophylline administration.

Authors:  J Mally; J H Connick; T W Stone
Journal:  Br J Pharmacol       Date:  1991-03       Impact factor: 8.739

10.  Relationship between protein binding and extravascular drug concentrations of a water-soluble drug, cytosine arabinoside.

Authors:  M L Slevin; A Johnston; R C Woollard; E M Piall; T A Lister; P Turner
Journal:  J R Soc Med       Date:  1983-05       Impact factor: 18.000

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.